Moving forward, the field must develop validated biomarkers of choline adequacy in free-living populations, harmonize intervention protocols, and define context-specific requirements across obesity, pregnancy, and glucagon-like peptide-1 (GLP-1)-based therapy use. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.